Miglustat: Substrate Reduction Therapy for Lysosomal Storage Disorders Associated with Primary Central Nervous System Involvement
Recent Patents on CNS Drug Discovery · 2006
DOI: 10.2174/157488906775245282 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Recent Patents on CNS Drug Discovery, 2006. Verfasst von Gregory M Pastores. Beteiligte Einrichtung: Neurogenetics Unit, Department of Neurology and Pediatrics, New York University School of Medicine, New York, NY, USA. gregory.pastores@med.nyu.edu. Die Arbeit wurde bisher 13-mal zitiert (Crossref).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Neurogenetics Unit, Department of Neurology and Pediatrics, New York University School of Medicine, New York, NY, USA. gregory.pastores@med.nyu.edu
Zitieren
APA
Pastores, G. M. (2006). Miglustat: Substrate Reduction Therapy for Lysosomal Storage Disorders Associated with Primary Central Nervous System Involvement. Recent Patents on CNS Drug Discovery. https://doi.org/10.2174/157488906775245282
Vancouver
Pastores GM. Miglustat: Substrate Reduction Therapy for Lysosomal Storage Disorders Associated with Primary Central Nervous System Involvement. Recent Patents on CNS Drug Discovery. 2006. doi:10.2174/157488906775245282
BibTeX
@article{Pastores2006,
author = {Pastores, Gregory M},
title = {Miglustat: Substrate Reduction Therapy for Lysosomal Storage Disorders Associated with Primary Central Nervous System Involvement},
journal = {Recent Patents on CNS Drug Discovery},
year = {2006},
doi = {10.2174/157488906775245282}
}
EUVIMED